Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease

Novavax’s partnership with Sanofi allows the pharma giant to explore potential combinations of assets from both companies, and it’s a blueprint for the kinds of alliances the vaccine developer is pursuing. Rather than commercializing vaccines, Novavax aims to turn its research into business development deals, R&D executive Ruxandra Draghia-Akli said. The post Novavax Sees Sanofi…

Read More

The Public Health Consequences of Public Housing Failures

Every year more than 10,000 taxpayer-supported public housing units are lost to disrepair. But federal lawmakers routinely ignore the full amount, around $115 billion, needed to keep the units in “decent, safe and sanitary” condition. One-time funds for public housing repairs were cut from the final version of the 2022 Inflation Reduction Act to appeal…

Read More

Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio

Sanofi’s Vicebio acquisition brings technology for developing vaccine combinations for multiple pathogens, such as RSV and hMPV. The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu. The post Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio appeared first on MedCity News.

Read More